Alzheimer’s Breakthrough: FDA Advisors Endorse Lilly’s Drug Donanemab for Disease Progression – What You Need to Know!
Washington, D.C. – A panel of independent advisers to the US Food and Drug Administration has recommended the endorsement of Eli Lilly’s drug donanemab on Monday. This drug, a monoclonal antibody, aims to slow the progression of early symptomatic Alzheimer’s disease by effectively removing amyloid plaque buildups in the brain, a hallmark of the disease. Statistics from the Alzheimer’s Association reveal that one in three older Americans dies with Alzheimer’s disease or another form of …